Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options


29 June 2020 - Novartis Pharma today announced that the Japanese Ministry of Health, Labour and Welfare simultaneously approved five new treatment options for Japanese patients:

  • Tabrecta (capmatinib) an oral MET inhibitor for MET exon 14 skipping mutation positive advanced and/or recurrent unresectable non-small cell lung cancer
  • Entresto (sacubitril valsartan sodium hydrate) in chronic heart failure
  • Mayzent (siponimod fumaric acid) in secondary progressive multiple sclerosis
  • Enerzair (glycopyrronium bromide, indacaterol acetate, mometasone furoate)
  • Atectura (indacaterol acetate, mometasone furoate) in different forms of asthma

Read Novartis press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Cancer , Outcome , Medicine , Japan